SEC Form 6-K filed by Innate Pharma S.A. ADS

11/8/24 6:00:41 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $IPHA alert in real time by email

6-K 1 a6k-iphx241108.htm 6-K Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: November 8, 2024

Commission File Number: 001-39084

Innate Pharma S.A.

(Translation of registrant's name into English)

Innate Pharma S.A.

117 Avenue de Luminy—BP 30191

13009 Marseille, France

+ 33 (0) 4 30 30 30

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]

EXHIBIT INDEX

Exhibit Description

99.1 Press Release dated November 8, 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INNATE PHARMA S.A.

Date: November 8, 2024 By: /s/ JONATHAN DICKINSON Name: Jonathan Dickinson

Title: Chairman of the Executive Board and Chief Executive Officer

Get the next $IPHA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IPHA

Date	Price Target	Rating	Analyst
9/17/2021	$7.00 → $9.00	Outperform	SVB Leerink
9/3/2021	$7.00	Mkt Perform → Outperform	SVB Leerink
9/3/2021		Market Perform → Outperform	SVB Leerink
9/2/2021		Market Perform → Outperform	SVB Leerink

More analyst ratings

Innate Pharma Releases Its 2025 Financial Calendar
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today released its 2025 financial calendar: March 27, 2025: Publication of 2024 financial statements May 13, 2025: Publication of revenue and cash position for 1Q2025 May 22, 2025: Annual General Shareholders Meeting September 17, 2025: Publication of half year financial statements November 13, 2025: Publication of revenue and cash position for 3Q2025 All financial reports are released before market open CET. All corporate information, such as the Company's financial statements and corporate presentations, is available in the Investors section on https://www.innate-pharma.com. Abou
11/20/24 1:00:00 AM ET
$IPHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL IPH6501 boosts NK cell proliferation and cytotoxicity, showing activity in vitro against a range of B-NHL cell lines, in vivo in various preclinical models and ex vivo in samples from R/R B-NHL patients In vivo studies further validated that IPH6501 augments the ability of peripheral NK cells to migrate and infiltrate tumors Results support clinical development of IPH6501 in R/R B-NHL Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced the publication in Science Immunology of preclinical data demonst
11/19/24 1:00:00 AM ET
$IPHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board Encouraging initial FDA feedback received on lacutamab regulatory pathway Lacutamab health-related quality of life and translational data to be presented at the upcoming ASH Annual Meeting IPH4502, a Nectin-4 ADC received FDA clearance of the IND to be developed in solid tumors Preclinical data for proprietary tetra-specific NK cell engager IPH6501 and novel ADC IPH4502 presented at SITC Cash position of €96.4 million1 as of September 30, 2024, anticipated cash runway to end of 2025 Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET Regulatory News: Innate Pharma SA
11/13/24 1:00:00 AM ET
$IPHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board Encouraging initial FDA feedback received on lacutamab regulatory pathway Lacutamab health-related quality of life and translational data to be presented at the upcoming ASH Annual Meeting IPH4502, a Nectin-4 ADC received FDA clearance of the IND to be developed in solid tumors Preclinical data for proprietary tetra-specific NK cell engager IPH6501 and novel ADC IPH4502 presented at SITC Cash position of €96.4 million1 as of September 30, 2024, anticipated cash runway to end of 2025 Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET Regulatory News: Innate Pharma SA
11/13/24 1:00:00 AM ET
$IPHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Wednesday, November 13, 2024, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2024. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Arvind Sood, Executive Vice President, President of US Operations Details for the Virtual Event The live webcast will be availa
11/7/24 1:00:00 AM ET
$IPHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Innate Pharma Reports First Half 2024 Business Update and Financial Results
Positive results with lacutamab from TELLOMAK Phase 2 study in mycosis fungoides presented at ASCO 2024 NK-Cell engager SAR443579/IPH61011 first-in-human study advanced to Phase 2 and initiation of front-line AML Phase 1/2 combination study Updated data from dose-escalation part presented at EHA 2024 confirm clinical benefit and durable responses in patients with R/R AML IPH45, proprietary anti Nectin-4 ADC progressing towards Phase 1 in H2 2024 Monalizumab data from AstraZeneca-sponsored Phase 2 study in early NSCLC presented at WCLC Cash position of €102.1 million2 as of June 30, 2024, anticipated cash runway to end of 2025 Conference call to be held today at 2:00 p.m. CEST
9/12/24 1:00:00 AM ET
$IPHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
Jonathan Dickinson joins Innate on November 1 and brings broad experience from leadership roles in biotech and big pharma Current interim CEO and co-founder Hervé Brailly will support the transition Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that its supervisory Board has appointed Jonathan Dickinson as the Company's new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process. Jonathan Dickinson most recently served as Executive Vice President and General Manager, Europe
10/14/24 1:00:00 AM ET
$IPHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
Two new Executive Board members appointed under recently announced interim CEO, Hervé Brailly Yannis Morel broadens remit to Chief Operating Officer Sonia Quaratino, Chief Medical Officer, appointed to the Executive Board Arvind Sood joins the Company and is appointed Executive Vice President, President of US Operations and to the Executive Board Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that it has strengthened the Company's leadership and corporate governance with the appointment of two new Executive Board members. Arvind Sood, Executive Vice President (EVP), President of US Operations, Dr Sonia Quaratino, EVP, Ch
1/4/24 12:59:00 AM ET
$IPHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Outcome of Innate Pharma's 2022 Annual General Meeting
Appointment of Dr Sally Bennett to the Supervisory Board Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") announced the voting results of its shareholders at the Annual General Meeting ("AGM"), which took place on May 20, 2022, in Marseille. All resolutions were voted on in accordance with the Executive Board's recommendations. A total of 134 votes were cast out of a total of 32,598,725 shares giving right to 33,088,040 voting rights, representing a quorum of 40.88%. The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2022 section of the Compan
5/20/22 4:00:00 PM ET
$IPHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care